Pertussis [strain BPZE1] vaccine is under clinical development by ILiAD Biotechnologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Pertussis [strain BPZE1] vaccine’s likelihood of approval (LoA) and phase transition for Pertussis (Whooping Cough) took place on 04 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pertussis [strain BPZE1] vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Pertussis [strain BPZE1] vaccine overview
Vaccine candidate is under development for prevention of whooping cough for adults and neonates, influenza A (H1N1/H3N2) infections, respiratory syntical virus infections, allergic airway inflammation and contact dermatitis and tuberculosis. The therapeutic candidate is a lyophilized live-attenuated pertussis vaccine. The vaccine candidate is administered through intranasal route. It constitutes of a mutated Bordetella strain.
ILiAD Biotechnologies overview
ILiAD Biotechnologies is a clinical-stage biotechnology company. It is headquartered in New York City, New York, the US.
Quick View Pertussis [strain BPZE1] vaccine LOA Data
|Highest Development Stage|